Macromolecular prodrug of dexamethasone prevents particle-induced peri-implant osteolysis with reduced systemic side effects

Ke Ren, Anand Dusad, Fang Yuan, Hongjiang Yuan, P. Edward Purdue, Edward V. Fehringer, Kevin Lloyd Garvin, Steven R. Goldring, Dong Wang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Aseptic implant loosening related to implant wear particle-induced inflammation is the most common cause of failure after joint replacement. Modulation of the inflammatory reaction to the wear products represents a rational approach for preventing aseptic implant failure. Long-term treatment using anti-inflammatory agents, however, can be associated with significant systemic side effects due to the drugs' lack of tissue specificity. To address this issue, N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-dexamethasone conjugate (P-Dex) was developed and evaluated for prevention of wear particle-induced osteolysis and the loss of fixation in a murine prosthesis failure model. Daily administration of free dexamethasone (Dex) was able to prevent wear particle-induced osteolysis, as assessed by micro-CT and histological analysis. Remarkably, monthly P-Dex administration (dose equivalent to free Dex treatment) was equally effective as free dexamethasone, but was not associated with systemic bone loss (a major adverse side effect of glucocorticoids). The reduced systemic toxicity of P-Dex is related to preferential targeting of the sites of wear particle-induced inflammation and its subcellular sequestration and retention by local inflammatory cell populations, resulting in sustained therapeutic action. These results demonstrate the feasibility of utilizing a macromolecular prodrug with reduced systemic toxicity to prevent wear particle-induced osteolysis.

Original languageEnglish (US)
Pages (from-to)1-9
Number of pages9
JournalJournal of Controlled Release
Volume175
Issue number1
DOIs
StatePublished - Feb 10 2014

Fingerprint

Osteolysis
Prodrugs
Dexamethasone
Replacement Arthroplasties
Prosthesis Failure
Inflammation
Organ Specificity
Glucocorticoids
Anti-Inflammatory Agents
Therapeutics
Bone and Bones
Pharmaceutical Preparations
Population

Keywords

  • Dexamethasone
  • ELVIS
  • HPMA copolymer
  • Implant loosening
  • Inflammation targeting
  • Prodrug

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Macromolecular prodrug of dexamethasone prevents particle-induced peri-implant osteolysis with reduced systemic side effects. / Ren, Ke; Dusad, Anand; Yuan, Fang; Yuan, Hongjiang; Purdue, P. Edward; Fehringer, Edward V.; Garvin, Kevin Lloyd; Goldring, Steven R.; Wang, Dong.

In: Journal of Controlled Release, Vol. 175, No. 1, 10.02.2014, p. 1-9.

Research output: Contribution to journalArticle

Ren, Ke ; Dusad, Anand ; Yuan, Fang ; Yuan, Hongjiang ; Purdue, P. Edward ; Fehringer, Edward V. ; Garvin, Kevin Lloyd ; Goldring, Steven R. ; Wang, Dong. / Macromolecular prodrug of dexamethasone prevents particle-induced peri-implant osteolysis with reduced systemic side effects. In: Journal of Controlled Release. 2014 ; Vol. 175, No. 1. pp. 1-9.
@article{08dd27231c5e448e88071760c9012c0e,
title = "Macromolecular prodrug of dexamethasone prevents particle-induced peri-implant osteolysis with reduced systemic side effects",
abstract = "Aseptic implant loosening related to implant wear particle-induced inflammation is the most common cause of failure after joint replacement. Modulation of the inflammatory reaction to the wear products represents a rational approach for preventing aseptic implant failure. Long-term treatment using anti-inflammatory agents, however, can be associated with significant systemic side effects due to the drugs' lack of tissue specificity. To address this issue, N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-dexamethasone conjugate (P-Dex) was developed and evaluated for prevention of wear particle-induced osteolysis and the loss of fixation in a murine prosthesis failure model. Daily administration of free dexamethasone (Dex) was able to prevent wear particle-induced osteolysis, as assessed by micro-CT and histological analysis. Remarkably, monthly P-Dex administration (dose equivalent to free Dex treatment) was equally effective as free dexamethasone, but was not associated with systemic bone loss (a major adverse side effect of glucocorticoids). The reduced systemic toxicity of P-Dex is related to preferential targeting of the sites of wear particle-induced inflammation and its subcellular sequestration and retention by local inflammatory cell populations, resulting in sustained therapeutic action. These results demonstrate the feasibility of utilizing a macromolecular prodrug with reduced systemic toxicity to prevent wear particle-induced osteolysis.",
keywords = "Dexamethasone, ELVIS, HPMA copolymer, Implant loosening, Inflammation targeting, Prodrug",
author = "Ke Ren and Anand Dusad and Fang Yuan and Hongjiang Yuan and Purdue, {P. Edward} and Fehringer, {Edward V.} and Garvin, {Kevin Lloyd} and Goldring, {Steven R.} and Dong Wang",
year = "2014",
month = "2",
day = "10",
doi = "10.1016/j.jconrel.2013.11.024",
language = "English (US)",
volume = "175",
pages = "1--9",
journal = "Journal of Controlled Release",
issn = "0168-3659",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Macromolecular prodrug of dexamethasone prevents particle-induced peri-implant osteolysis with reduced systemic side effects

AU - Ren, Ke

AU - Dusad, Anand

AU - Yuan, Fang

AU - Yuan, Hongjiang

AU - Purdue, P. Edward

AU - Fehringer, Edward V.

AU - Garvin, Kevin Lloyd

AU - Goldring, Steven R.

AU - Wang, Dong

PY - 2014/2/10

Y1 - 2014/2/10

N2 - Aseptic implant loosening related to implant wear particle-induced inflammation is the most common cause of failure after joint replacement. Modulation of the inflammatory reaction to the wear products represents a rational approach for preventing aseptic implant failure. Long-term treatment using anti-inflammatory agents, however, can be associated with significant systemic side effects due to the drugs' lack of tissue specificity. To address this issue, N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-dexamethasone conjugate (P-Dex) was developed and evaluated for prevention of wear particle-induced osteolysis and the loss of fixation in a murine prosthesis failure model. Daily administration of free dexamethasone (Dex) was able to prevent wear particle-induced osteolysis, as assessed by micro-CT and histological analysis. Remarkably, monthly P-Dex administration (dose equivalent to free Dex treatment) was equally effective as free dexamethasone, but was not associated with systemic bone loss (a major adverse side effect of glucocorticoids). The reduced systemic toxicity of P-Dex is related to preferential targeting of the sites of wear particle-induced inflammation and its subcellular sequestration and retention by local inflammatory cell populations, resulting in sustained therapeutic action. These results demonstrate the feasibility of utilizing a macromolecular prodrug with reduced systemic toxicity to prevent wear particle-induced osteolysis.

AB - Aseptic implant loosening related to implant wear particle-induced inflammation is the most common cause of failure after joint replacement. Modulation of the inflammatory reaction to the wear products represents a rational approach for preventing aseptic implant failure. Long-term treatment using anti-inflammatory agents, however, can be associated with significant systemic side effects due to the drugs' lack of tissue specificity. To address this issue, N-(2-hydroxypropyl) methacrylamide (HPMA) copolymer-dexamethasone conjugate (P-Dex) was developed and evaluated for prevention of wear particle-induced osteolysis and the loss of fixation in a murine prosthesis failure model. Daily administration of free dexamethasone (Dex) was able to prevent wear particle-induced osteolysis, as assessed by micro-CT and histological analysis. Remarkably, monthly P-Dex administration (dose equivalent to free Dex treatment) was equally effective as free dexamethasone, but was not associated with systemic bone loss (a major adverse side effect of glucocorticoids). The reduced systemic toxicity of P-Dex is related to preferential targeting of the sites of wear particle-induced inflammation and its subcellular sequestration and retention by local inflammatory cell populations, resulting in sustained therapeutic action. These results demonstrate the feasibility of utilizing a macromolecular prodrug with reduced systemic toxicity to prevent wear particle-induced osteolysis.

KW - Dexamethasone

KW - ELVIS

KW - HPMA copolymer

KW - Implant loosening

KW - Inflammation targeting

KW - Prodrug

UR - http://www.scopus.com/inward/record.url?scp=84890902145&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890902145&partnerID=8YFLogxK

U2 - 10.1016/j.jconrel.2013.11.024

DO - 10.1016/j.jconrel.2013.11.024

M3 - Article

VL - 175

SP - 1

EP - 9

JO - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

IS - 1

ER -